As seen on
Pioneering Botanical Drug Development
Ajna is creating transformative therapies that hold the potential to revolutionize medicine and enhance the lives of countless individuals around the world.
FIRST MOVERS:
With only 4 currently FDA-approved botanical drugs, Ajna is strategically positioned.
SPEED TO MARKET:
Selected plant species have a well-established history of therapeutic use.
UNIQUE IP:
The intricate composition of our botanical mixtures makes them nearly impossible to replicate.
THE PROBLEM
People want natural pharmaceutical options, but few exist.
Plant medicines have been trusted for millennia, offering therapeutic benefits deeply rooted in cultural and historical practices. As modern pharmaceuticals often have unintended side effects, a growing demand for botanical alternatives is evident. Ajna is building a bridge between what people want, and physician advocacy they can trust.
THE SOLUTION
Ajna BioSciences is creating FDA-approved botanical medicines by combining nature’s healing power with pharmaceutical precision.
With a pipeline targeting Autism Spectrum Disorders (ASD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD), we bridge the gap between traditional medicine and modern healthcare, delivering clinically validated FDA approved solutions.
We are solving this problem by pioneering FDA-approved botanical pharmaceuticals—safe, effective, and backed by rigorous clinical research. Our approach combines:
-
Advanced Drug Development
We apply modern Chemistry Manufacturing, and Controls (CMC) to ensure safety, efficacy, consistency, and pharmaceutical-grade quality in every formulation.
-
Regulatory Expertise
Our team, including FDA veterans, navigates the complex approval process to bring botanical drugs to market with the highest safety and efficacy standards.
-
Cutting-Edge Clinical Research
Through rigorous preclinical and clinical trials, we provide the scientific validation needed to integrate botanical therapies into mainstream medicine.
-
A Robust Drug Pipeline
We are developing full-spectrum cannabinoid and psilocybin-based medicines to address critical unmet medical needs, including Autism Spectrum Disorder (ASD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD).
Ajna's Competitive Advantage
SPECIALIZED INFRASTRUCTURE
Our 13,500 ft² Denver Headquarters combines state-of-the-art cultivation, extraction, and analytical instrumentation built for rapid drug discovery and development.
With decades of expertise, our scientists excel in drug development, botanical standardization, and FDA-compliant substance characterization for botanical extracts.
CHEMISTRY MANUFACTURING, & CONTROLS (CMC)
With decades of collective expertise, our scientists excel in drug development, botanical standardization, and substance characterization, ensuring compliance with the FDA’s rigorous chemistry, manufacturing, and controls criteria for complex botanical extracts.
REGULATORY SENSITIVITY
Our FDA veterans, with 500+ IND/NDA reviews and 60+ years in natural product development, provide unmatched expertise in botanical pharmacology and regulation.
Backed by top researchers, Chief Medical Advisor Dr. Orrin Devinsky led the Epidiolex™ investigation, the first FDA-approved cannabis drug.
CLINICAL EXPERTISE
Backed by elite medical researchers and specialists in neurology, autism, epilepsy, and psychiatry. Our Chief Medical Advisor, Dr. Orrin Devinsky, led the principal investigation for Epidolex™, the sole FDA-approved cannabis drug.